Exenatide Microspheres
Brand name: Bydureon Bcise
Rank #235 of 500 drugs by total cost
$56.6M
Total Cost
48,670
Total Claims
$56.6M
Total Cost
2,660
Prescribers
$1,162
Cost per Claim
1,443
Beneficiaries
67,010
30-Day Fills
$21K
Avg Cost/Provider
18
Avg Claims/Provider
About Exenatide Microspheres
Exenatide Microspheres (sold as Bydureon Bcise) was prescribed 48,670 times by 2,660 Medicare Part D providers in 2023, costing the program $56.6M. At $1,162 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 232 | Lumateperone Tosylate (Caplyta) | $57.4M | 35,791 |
| 233 | Everolimus (Everolimus) | $57.0M | 8,962 |
| 234 | Allopurinol (Allopurinol) | $56.9M | 3,852,206 |
| 235 | Exenatide Microspheres (Bydureon Bcise) | $56.6M | 48,670 |
| 236 | Valsartan (Valsartan) | $56.4M | 1,481,937 |
| 237 | Benralizumab (Fasenra Pen) | $54.8M | 9,334 |
| 238 | Netarsudil Mesylat/Latanoprost (Rocklatan) | $54.7M | 103,171 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology